{"id":7604,"date":"2005-03-29T14:37:39","date_gmt":"2005-03-29T13:37:39","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=7604"},"modified":"2014-05-22T14:50:04","modified_gmt":"2014-05-22T14:50:04","slug":"ritonavir-boosting-may-not-overcome-interaction-between-atazanavir-and-nevirapine","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/7604","title":{"rendered":"Ritonavir boosting may not overcome interaction between atazanavir and nevirapine"},"content":{"rendered":"<p><strong>Graham McKerrow, HIV i-Base<\/strong><\/p>\n<p><strong>A poster by Christopher S Alexander and colleagues from the British Columbia Centre for excellence in HIV\/AIDS, Vancouver, Canada, looked at the interaction between atazanavir\/ritonavir (ATZ\/rtv) and nevirapine (NVP) and\/or tenofovir (TDF) as observed in a clinical setting. The results suggest that RTV boosting of ATV reduces the interaction with TDF but it may not do the same with NVP.<\/strong><\/p>\n<p>It is recommended to boost ATZ with RTV (300\/100mg) when administered with TDF but the interaction between NVP and ATZ has not previously been reported. Alexander and colleagues looked at HIV-positive adults taking regimens that included ATZ\/rtv once daily. After at least two weeks of treatment, blood samples were taken at the Ctrough and 1, 2 and 3 hours post dose.<\/p>\n<p>There was no significant difference in the median ATZ concentrations for those on ATZ\/rtv only or for those also taking TDF. But the researchers did observe a trend towards reduced ATV concentrations in patients who also took NVP with or without TDF.<\/p>\n<p>The poster did not report the number of patients included in the study.<\/p>\n<p>Reference:<\/p>\n<p>Alexander C, Montaner J, Langridge S et al. Interaction between atazanavir\/ritonavir (ATV\/rtv) and nevirapine (NVP) is observed in a clinical setting. 7th ICDTHI,14-18 Nov, 2004, Glasgow. Abstract P275.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Graham McKerrow, HIV i-Base A poster by Christopher S Alexander and colleagues from the British Columbia Centre for excellence in HIV\/AIDS, Vancouver, Canada, looked at the interaction between atazanavir\/ritonavir (ATZ\/rtv) and nevirapine (NVP) and\/or tenofovir (TDF) as observed in a &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,3],"tags":[83],"class_list":["post-7604","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-antiretrovirals","tag-hiv-7-glasgow-2004"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7604","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=7604"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/7604\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=7604"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=7604"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=7604"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}